These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 23326464)

  • 1. Adverse events in healthy individuals and MDR-TB contacts treated with anti-tuberculosis drugs potentially effective for preventing development of MDR-TB: a systematic review.
    Langendam MW; Tiemersma EW; van der Werf MJ; Sandgren A
    PLoS One; 2013; 8(1):e53599. PubMed ID: 23326464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lack of evidence to support policy development for management of contacts of multidrug-resistant tuberculosis patients: two systematic reviews.
    van der Werf MJ; Langendam MW; Sandgren A; Manissero D
    Int J Tuberc Lung Dis; 2012; 16(3):288-96. PubMed ID: 22640442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Levofloxacin versus placebo for the prevention of tuberculosis disease in child contacts of multidrug-resistant tuberculosis: study protocol for a phase III cluster randomised controlled trial (TB-CHAMP).
    Seddon JA; Garcia-Prats AJ; Purchase SE; Osman M; Demers AM; Hoddinott G; Crook AM; Owen-Powell E; Thomason MJ; Turkova A; Gibb DM; Fairlie L; Martinson N; Schaaf HS; Hesseling AC
    Trials; 2018 Dec; 19(1):693. PubMed ID: 30572905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness and safety of tuberculosis preventive treatment for contacts of patients with multidrug-resistant tuberculosis: a systematic review and meta-analysis.
    Zhou G; Luo S; He J; Chen N; Zhang Y; Cai S; Guo X; Chen H; Song C
    Clin Microbiol Infect; 2024 Feb; 30(2):189-196. PubMed ID: 37741621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Limited Effect of Later-Generation Fluoroquinolones in the Treatment of Ofloxacin-Resistant and Moxifloxacin-Susceptible Multidrug-Resistant Tuberculosis.
    Lee H; Ahn S; Hwang NY; Jeon K; Kwon OJ; Huh HJ; Lee NY; Kim CK; Koh WJ
    Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29203478
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.
    Lee M; Mok J; Kim DK; Shim TS; Koh WJ; Jeon D; Lee T; Lee SH; Kim JS; Park JS; Lee JY; Kim SY; Lee JH; Jo KW; Jhun BW; Kang YA; Ahn JH; Kim CK; Shin S; Song T; Shin SJ; Kim YR; Ahn H; Hahn S; Won HJ; Jang JY; Cho SN; Yim JJ
    Trials; 2019 Jan; 20(1):57. PubMed ID: 30651149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment for LTBI in contacts of MDR-TB patients, Federated States of Micronesia, 2009-2012.
    Bamrah S; Brostrom R; Dorina F; Setik L; Song R; Kawamura LM; Heetderks A; Mase S
    Int J Tuberc Lung Dis; 2014 Aug; 18(8):912-8. PubMed ID: 25199004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fluoroquinolones for the treatment of tuberculosis in children.
    Thee S; Garcia-Prats AJ; Donald PR; Hesseling AC; Schaaf HS
    Tuberculosis (Edinb); 2015 May; 95(3):229-45. PubMed ID: 25797610
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis.
    Centers for Disease Control and Prevention
    MMWR Recomm Rep; 2013 Oct; 62(RR-09):1-12. PubMed ID: 24157696
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment and outcomes in children with multidrug-resistant tuberculosis: A systematic review and individual patient data meta-analysis.
    Harausz EP; Garcia-Prats AJ; Law S; Schaaf HS; Kredo T; Seddon JA; Menzies D; Turkova A; Achar J; Amanullah F; Barry P; Becerra M; Chan ED; Chan PC; Ioana Chiotan D; Crossa A; Drobac PC; Fairlie L; Falzon D; Flood J; Gegia M; Hicks RM; Isaakidis P; Kadri SM; Kampmann B; Madhi SA; Marais E; Mariandyshev A; Méndez-Echevarría A; Moore BK; Nargiza P; Ozere I; Padayatchi N; Ur-Rehman S; Rybak N; Santiago-Garcia B; Shah NS; Sharma S; Shim TS; Skrahina A; Soriano-Arandes A; van den Boom M; van der Werf MJ; van der Werf TS; Williams B; Yablokova E; Yim JJ; Furin J; Hesseling AC;
    PLoS Med; 2018 Jul; 15(7):e1002591. PubMed ID: 29995958
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors for multidrug-resistant tuberculosis among HIV-infected patients and response to specific drug regimens. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clinical Trials Group (ACTG), National Institutes for Health.
    Telzak EE; Chirgwin KD; Nelson ET; Matts JP; Sepkowitz KA; Benson CA; Perlman DC; El-Sadr WM
    Int J Tuberc Lung Dis; 1999 Apr; 3(4):337-43. PubMed ID: 10206505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Global policies and practices for managing persons exposed to multidrug-resistant tuberculosis.
    Cain KP; Nelson LJ; Cegielski JP
    Int J Tuberc Lung Dis; 2010 Mar; 14(3):269-74. PubMed ID: 20132616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is hypothyroidism rare in multidrug resistance tuberculosis patients on treatment? A systematic review and meta-analysis.
    Tola HH; Holakouie-Naieni K; Lejisa T; Mansournia MA; Yaseri M; Tesfaye E; Mola M
    PLoS One; 2019; 14(6):e0218487. PubMed ID: 31211809
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exposed! Management of MDR-TB household contacts in an evidence light era.
    Gaskell KM; Allen R; Moore DAJ
    Int J Infect Dis; 2019 Mar; 80S():S13-S16. PubMed ID: 30825653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adverse Events Associated With the Treatment of Multidrug-Resistant Tuberculosis: A Systematic Review and Meta-analysis.
    Wu S; Zhang Y; Sun F; Chen M; Zhou L; Wang N; Zhan S
    Am J Ther; 2016; 23(2):e521-30. PubMed ID: 24284652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative roles of moxifloxacin and levofloxacin in the treatment of pulmonary multidrug-resistant tuberculosis: a retrospective study.
    Jiang RH; Xu HB; Li L
    Int J Antimicrob Agents; 2013 Jul; 42(1):36-41. PubMed ID: 23582696
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frequency of adverse events observed with second-line drugs among patients treated for multidrug-resistant tuberculosis.
    Prasad R; Singh A; Srivastava R; Hosmane GB; Kushwaha RA; Jain A
    Indian J Tuberc; 2016 Apr; 63(2):106-14. PubMed ID: 27451820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adverse events related to multidrug-resistant tuberculosis treatment, Latvia, 2000-2004.
    Bloss E; Kuksa L; Holtz TH; Riekstina V; Skripconoka V; Kammerer S; Leimane V
    Int J Tuberc Lung Dis; 2010 Mar; 14(3):275-81. PubMed ID: 20132617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chinese herbal medicine as adjuvant treatment to chemotherapy for multidrug-resistant tuberculosis (MDR-TB): A systematic review of randomised clinical trials.
    Wang M; Guan X; Chi Y; Robinson N; Liu JP
    Tuberculosis (Edinb); 2015 Jul; 95(4):364-72. PubMed ID: 25861717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Impact of Preventive Treatment for Multidrug- and Rifampin-Resistant Tuberculosis Exceeds Trial-Based Estimates.
    Kasaie P; Pennington J; Gupta A; Dowdy DW; Kendall EA
    Clin Infect Dis; 2024 Jan; 78(1):133-143. PubMed ID: 37724763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.